Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay,Isabelle Soerjomataram,Rajesh Dikshit,Sultan Eser,Colin Mathers,Marise Souto Rebelo,Donald Maxwell Parkin,David Forman,Freddie Bray +8 more
Reads0
Chats0
TLDR
The GLOBOCAN series of the International Agency for Research on Cancer (IARC) as mentioned in this paper provides estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012.Abstract:
Estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012 are now available in the GLOBOCAN series of the International Agency for Research on Cancer. We review the sources and methods used in compiling the national cancer incidence and mortality estimates, and briefly describe the key results by cancer site and in 20 large “areas” of the world. Overall, there were 14.1 million new cases and 8.2 million deaths in 2012. The most commonly diagnosed cancers were lung (1.82 million), breast (1.67 million), and colorectal (1.36 million); the most common causes of cancer death were lung cancer (1.6 million deaths), liver cancer (745,000 deaths), and stomach cancer (723,000 deaths).read more
Citations
More filters
Journal ArticleDOI
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Marko Babjuk,Maximilian Burger,Richard Zigeuner,Shahrokh F. Shariat,Bas W.G. van Rhijn,Eva Comperat,Richard Sylvester,Eero Kaasinen,Andreas Böhle,Joan Palou Redorta,Morgan Rouprêt +10 more
TL;DR: The European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (NMIBC) were published in 2013 and the levels of evidence and grades of recommendation were assigned.
Journal ArticleDOI
Cancer statistics for the year 2020: An overview
Jacques Ferlay,Murielle Colombet,Isabelle Soerjomataram,Donald Maxwell Parkin,Donald Maxwell Parkin,Marion Piñeros,Ariana Znaor,Freddie Bray +7 more
TL;DR: This paper reviewed the data sources and methods used in compiling the International Agency for Research on Cancer (IARC) GLOBOCAN cancer statistics for the year 2020 and summarised the main results.
Journal ArticleDOI
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang,Narikazu Boku,Taroh Satoh,Min Hee Ryu,Yee Chao,Ken Kato,Hyun Cheol Chung,Jen-Shi Chen,Kei Muro,Won Ki Kang,Kun-Huei Yeh,Takaki Yoshikawa,Sang Cheul Oh,Li Yuan Bai,Takao Tamura,Keun Wook Lee,Yasuo Hamamoto,Jong Gwang Kim,Keisho Chin,Do Youn Oh,Keiko Minashi,Jae Yong Cho,Masahiro Tsuda,Li-Tzong Chen,Li-Tzong Chen +24 more
TL;DR: In this phase 3 study, the survival benefits indicate that nivolumab might be a new treatment option for heavily pretreated patients with advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou-Alfa,Tim Meyer,Ann-Lii Cheng,Anthony B. El-Khoueiry,Lorenza Rimassa,Baek Yeol Ryoo,Irfan Cicin,Philippe Merle,Yen-Hsun Chen,Joong-Won Park,Jean-Frédéric Blanc,Luigi Bolondi,Heinz Josef Klümpen,Heinz Josef Klümpen,Stephen L. Chan,Vittorina Zagonel,Tiziana Pressiani,Min Hee Ryu,Alan P. Venook,Alan P. Venook,Colin Hessel,Anne E. Borgman-Hagey,Gisela Schwab,Robin Kate Kelley +23 more
TL;DR: Treatment with cabozantinib resulted in longer overall survival and progression‐free survival than placebo among patients with previously treated advanced hepatocellular carcinoma, and the rate of high‐grade adverse events in the cabozaninib group was approximately twice that observed in the placebo group.
Journal ArticleDOI
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.
TL;DR: Studies now aim to identify molecular markers and imaging techniques that can detect patients with HCC at earlier stages and better predict their survival time and response to treatment.
References
More filters
Journal ArticleDOI
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
TL;DR: The results for 20 world regions are presented, summarizing the global patterns for the eight most common cancers, and striking differences in the patterns of cancer from region to region are observed.
Book
Cancer Incidence in Five Continents
Freddie Bray,J. Ferlay,Mathieu Laversanne,David H. Brewster,C. Gombe Mbalawa,B. Kohler,Marion Piñeros,Eva Steliarova-Foucher,Rajaraman Swaminathan,Sebastien Antoni,Isabelle Soerjomataram,David Forman +11 more
TL;DR: The aim of this study was to establish a database of histological groups and to provide a level of consistency and quality of data that could be applied in the design of future registries.
Journal ArticleDOI
International Statistical Classification of Diseases and Related Health Problems
TL;DR: There is substantial global variation in the relative burden of stroke compared with IHD, and the disproportionate burden from stroke for many lower-income countries suggests that distinct interventions may be required.
Journal ArticleDOI
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
J. Ferlay,Eva Steliarova-Foucher,Joannie Lortet-Tieulent,Sonia Rosso,Jan Willem Coebergh,Harry Comber,David Forman,Freddie Bray +7 more
TL;DR: Up-to-date estimates of the cancer burden in Europe alongside the description of the varying distribution of common cancers at both the regional and country level provide a basis for establishing priorities to cancer control actions in Europe.